Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment

[1]  Steward L. Davis,et al.  Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy , 1980, Cancer.

[2]  M. Shah,et al.  An effective low‐dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients , 1980, Cancer.

[3]  I. Henderson,et al.  Cancer of the breast: the past decade (first of two parts). , 1980, The New England journal of medicine.

[4]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[5]  R. Santen,et al.  A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer , 1979, Cancer.

[6]  L. Cacciari,et al.  Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. , 1979, European journal of cancer.

[7]  S. Jones,et al.  Comparative trial of low‐dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer , 1979, Cancer.

[8]  H. Mouridsen,et al.  Tamoxifen in advanced breast cancer. , 1978, Cancer treatment reviews.

[9]  A. Weiss,et al.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity , 1977, Cancer.

[10]  B. Hoogstraten,et al.  Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.

[11]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[12]  S. Carter.  Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. , 1976, Cancer treatment reviews.

[13]  A. Weiss,et al.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. , 1976, Cancer treatment reports.

[14]  S. George,et al.  Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study , 1976, Cancer.

[15]  S. Carter.  Adriamycin-a review. , 1975, Journal of the National Cancer Institute.

[16]  D. Ahmann,et al.  Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. , 1974, Cancer chemotherapy reports.

[17]  B. Hoogstraten,et al.  Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A southwest cancer chemotherapy study group study , 1974, Cancer.

[18]  G. Bonadonna,et al.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy , 2004, Cancer Chemotherapy and Pharmacology.

[19]  T. Landberg,et al.  A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. , 1982, Clinical therapeutics.

[20]  T. Pajak,et al.  Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. , 1980, Cancer treatment reports.